Clinical trials: insulin glargine
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)
The main reason for this study is to compare the study drug tirzepatide to insulin glargine in participants with type 2 diabetes on metformin with or without a sulfonylurea.
- Trial name
- NCT04093752
- Testing
- Tirzepatide, Insulin Glargine
- Where
- 67 sites in Australia, China and 2 more
- Volunteers
- 917 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes, Renal Insufficiency
Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency
It is imperative to devise easy to follow, yet appropriate, guidelines for insulin use in renal-impaired patients. This will be done by comparing two regimens: 1) glargine once daily plus mealtime glulisine based on weight alone…
- Trial name
- NCT00911625
- Testing
- 0.5 units/kg daily insulin, 0.25 units/kg daily insulin
- Where
- 3 sites in United States
- Volunteers
- 114 people
- Sponsor
- Loyola University
Diabetes Mellitus, Type 1
Test of the Efficacy and Safety of Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus
Primary Objective: To evaluate the efficacy and the safety of insulin glulisine in type I Diabetes Melittus (DM) patients Secondary Objective: To evaluate the insulin glulisine doses To assess the patient satisfaction
- Trial name
- PORTAL 1 (NCT00964574)
- Testing
- INSULIN GLULISINE (HMR1964), INSULIN GLARGINE
- Where
- Belarus
- Volunteers
- 68 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1
A Study of Insulin Peglispro and Glargine on Fats in Participants With Type 1 Diabetes
This study has two parts. Each participant will receive a daily injection of insulin peglispro during one treatment period and a daily injection of insulin glargine during the other treatment period.
- Trial name
- NCT01771250
- Testing
- Insulin Peglispro, Insulin Glargine
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)
This trial will assess the safety and efficacy of omarigliptin (MK-3102) compared with the sulfonylurea, glimepiride, in Type 2 diabetes mellitus participants with inadequate glycemic control on metformin monotherapy.
- Trial name
- NCT01682759
- Testing
- Omarigliptin, Glimepiride, Metformin
- Volunteers
- 751 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 1
GABA and Beta-cell Regeneration
GABA(gamma-Aminobutyric acid) may be used for decreasing anti-gad antibodies and leads beta-cell regeneration.
- Trial name
- NCT04375020
- Testing
- GABA
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Ministry of Health and Population, Egypt
Diabetes Mellitus, Type 2
Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin
This is a multicenter, comparator-controlled, open-label, randomized, two-arm, parallel trial to compare the effect of exenatide twice daily and insulin glargine on glycemic control, as measured by hemoglobin A1c (HbA1c).
- Trial name
- NCT00082381
- Testing
- Exenatide (AC2993), Insulin glargine
- Where
- 91 sites in United States, Australia and 11 more
- Volunteers
- 551 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes
Evidence regarding optimal methods of insulin dose adjustment is lacking in the literature. The purpose of this study is to evaluate the efficacy and safety of two approaches to escalate prandial insulin therapy in participants…
- Trial name
- AUTONOMY (NCT01215955)
- Testing
- Insulin lispro, Glargine
- Where
- 76 sites in United States, Argentina and 13 more
- Volunteers
- 1,117 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
A Study in Participants With Type I Diabetes Mellitus
The purpose of this study is: To compare blood sugar control on LY2605541 with insulin glargine after 52 weeks of treatment. To compare the rate of nocturnal low blood sugar episodes on LY2605541 with insulin glargine during 52…
- Trial name
- IMAGINE 3 (NCT01454284)
- Testing
- Glargine, LY2605541, Insulin Lispro
- Where
- 119 sites in United States, Australia and 18 more
- Volunteers
- 1,114 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes (T2DM)
Influence of Gut Microbiota on the Development of Type 2 Diabetes Mellitus and Personalization of Diabetes-lowing Therapy
An observational, single-center, prospective study was conducted to examine the impact of CM on the development of T2DM and the personalization of initial SST in patients with newly diagnosed T2DM who had not previously received…
- Trial name
- GM (NCT07627048)
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- Pirogov Russian National Research Medical University
Diabetes Mellitus, Type 2 Treated With Insulin
Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue
The association of insulin degludec with liraglutide in the same device (IDegLira) is a potent but at the same time safe drug that reduces the risk of hypoglycemia when compared to a basal or basal-bolus insulin schedule.
- Trial name
- NCT05767255
- Testing
- insulin degludec + liraglutide, Insulin Glargine - Insulin Aspart
- Where
- Colombia
- Volunteers
- 66 people
- Sponsor
- Hospital Universitario San Ignacio
Healthy
A Study to Compare LY2963016 and US-approved Lantus® After Single Dose Administration to Healthy Participants
The purpose of this study is to compare the pharmacokinetics and pharmacodynamics of LY2963016 and US-approved Lantus®. The study involves four single injections; two doses of LY2963016 and two doses of US-approved Lantus®.
- Trial name
- NCT01688635
- Testing
- LY2963016, US Approved Lantus
- Where
- Singapore
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Biphasic Insulin Aspart 30 in Combination With Metformin in Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to investigate the efficacy on blood glucose control in type 2 diabetes.
- Trial name
- EUROMIX (NCT00619697)
- Testing
- biphasic insulin aspart, insulin glargine, metformin
- Where
- 54 sites in Austria, Czechia and 5 more
- Volunteers
- 260 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus
Immunogenicity Study of Insulin Glargine Ezelin vs Lantus in Type 2 Diabetes Mellitus Patients
This is an open-label randomised multicenter clinical study to compare immunogenicity of the drug products Insulin Glargine (Kalbe Farma) and Lantus (Sanofi -Aventis) in type 2 diabetes mellitus patients
- Trial name
- NCT03352674
- Testing
- Insulin Glargine Ezelin, Insulin Glargine Pen Injector [Lantus]
- Where
- Indonesia
- Volunteers
- 133 people
- Sponsor
- Universitas Indonesia
Hyperglycemia, Cardiovascular Diseases
REsearching Coronary REduction by Appropriately Targeting Euglycemia (RECREATE Pilot Study)
Insulin will safely reduce glucose levels in patients with acute ST-elevation myocardial infarction and admission hyperglycemia.
- Conditions
- Hyperglycemia, Cardiovascular Diseases, Myocardial Infarction
- Trial name
- RECREATE Pilot (NCT00640991)
- Testing
- glulisine insulin, glargine insulin
- Where
- 13 sites in Argentina, Canada and 1 more
- Volunteers
- 500 people
- Sponsor
- Population Health Research Institute
Type 2 Diabetes
Levemir-Body Composition and Energy Metabolism
The objectives is to compare the changes in body composition (primary objective), diabetes parameters, energy expenditure and energy intake between Insulin detemir (Levemir® - Novolin® 4 pen) and insulin glargine (Lantus® …
- Trial name
- NCT00862875
- Testing
- Detemir or Glargine
- Where
- Canada
- Volunteers
- 42 people
- Sponsor
- Institut de Recherches Cliniques de Montreal
Diabetes Mellitus, Type 2
Glycemic Optimization Treatment Study
To compare the frequency of severe hypoglycemia events for 5 dosing algorithms of Lantus®, each of varying intensity and defined by their end-of -study target for self monitored plasma glucose(SMPG), in patients with Type 2…
- Trial name
- GOT (NCT00552370)
- Testing
- Lantus®
- Volunteers
- 5,062 people
- Sponsor
- Sanofi
Hyperglycemia, Leukemia
Intensive Glycemic Control on Infectious Morbidity In Patients With Acute Leukemia
RATIONALE: Controlling blood sugar levels may be effective in preventing infections in patients receiving chemotherapy for acute myeloid leukemia or acute lymphoblastic leukemia.
- Trial name
- NCT00943709
- Testing
- insulin glargine recombinant, therapeutic insulin
- Where
- United States
- Sponsor
- University of Medicine and Dentistry of New Jersey
Type 2 Diabetes
Prospective Influence of Bedtime Insulin Glargine on Mobilization and Function of Endothelial Progenitor Cells
In this trial, it will be studied whether early addition of the long acting insulin analogue Glargine is capable of increasing the number and differentiation of endothelial progenitor cells (EPC) in patients with type 2 diabetes…
- Trial name
- NCT00523393
- Testing
- Insulin Glargin, Human Insulin
- Where
- Germany
- Volunteers
- 75 people
- Sponsor
- Heidelberg University
Diabetes Mellitus, Type 2
Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes
The primary objective of this study is to show that a prandial insulin regimen, consisting of premeal insulin lispro "mid mixture" (or a combined regimen of insulin lispro "mid mixture" and insulin lispro "low mixture") plus…
- Trial name
- NCT00191464
- Testing
- premeal insulin lispro mixtures, insulin glargine, metformin
- Where
- 7 sites in United States, Australia and 5 more
- Volunteers
- 320 people
- Sponsor
- Eli Lilly and Company